We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

15 hedge funds and large institutions have $249K invested in InMed Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 14 → 15 (+1)

0.2% less ownership

Funds ownership: 0.76% → 0.57% (-0.2%)

25% less capital invested

Capital invested by funds: $334K → $249K (-$85.2K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$22.4K
2
TSS
Two Sigma Securities
New York
+$926
3
BL
BFSG LLC
California
+$74
4
AF
Advisornet Financial
Minnesota
+$29
5
UBS Group
UBS Group
Switzerland
+$15

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$55.2K
2
Citadel Advisors
Citadel Advisors
Florida
-$7.82K
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.9K
4
TWC
TD Waterhouse Canada
Ontario, Canada
-$43
5
ASN
Advisory Services Network
Georgia
-$25
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$132K -$55.2K -7,511 -29%
AC
2
Armistice Capital
New York
$97.2K +$22.4K +3,050 +30%
Renaissance Technologies
3
Renaissance Technologies
New York
$10K -$3.9K -530 -27%
TSS
4
Two Sigma Securities
New York
$5.61K +$926 +126 +20%
Citadel Advisors
5
Citadel Advisors
Florida
$4.48K -$7.82K -1,064 -63%
BL
6
BFSG LLC
California
$73 +$74 +10 New
Qube Research & Technologies (QRT)
7
Qube Research & Technologies (QRT)
United Kingdom
$70 – – –
Bank of America
8
Bank of America
North Carolina
$36 – – –
AF
9
Advisornet Financial
Minnesota
$29 +$29 +4 New
UBS Group
10
UBS Group
Switzerland
$15 +$15 +2 New
Osaic Holdings
11
Osaic Holdings
Arizona
$13 – – –
AWM
12
AllSquare Wealth Management
New York
$8 – – –
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$7 – – –
National Bank of Canada
14
National Bank of Canada
Quebec, Canada
$3 – – –
GRP
15
Global Retirement Partners
California
$2 – – –
Toronto Dominion Bank
16
Toronto Dominion Bank
Ontario, Canada
$1 – – –
TWC
17
TD Waterhouse Canada
Ontario, Canada
– -$43 -4 Closed
ASN
18
Advisory Services Network
Georgia
– -$25 -3 Closed

INM Hedge Fund Activity: Q1 2024 in Review

15 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q1 2024, worth a combined $249K — down 25% from $334K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new INM positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, adding an estimated $22.4K. The largest seller was Sabby Management, cutting an estimated $55.2K.

  • 15 institutional investors held InMed Pharmaceuticals (INM) as of Q1 2024, up from 14 in Q4 2023.
  • Funds reported $249K of InMed Pharmaceuticals stock for Q1 2024, down 25% quarter-over-quarter.
  • 3 funds opened new InMed Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of +1 holder.
  • The largest InMed Pharmaceuticals buyer in Q1 2024 was Armistice Capital, an estimated $22.4K added.
  • The largest InMed Pharmaceuticals seller in Q1 2024 was Sabby Management, an estimated $55.2K sold.

Based on aggregated 13F filings for Q1 2024.